We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva Plunges to 10-Year Low, Credit Rating in Jeopardy
Read MoreHide Full Article
Shares of Teva Pharmaceuticals (TEVA - Free Report) , a favorite for investors chasing large dividend yields, fell more than 4.4%—and hit a 10-year intraday low—on Wednesday. Just says after the company reported sluggish Q2 earnings, investors are continuing to ditch the stock amid reports that Teva is desperately trying to sell off assets.
According to sources cited by Bloomberg, Teva is looking to ramp up asset sales in an effort to preserve its credit rating and cut its mounting debt. The report claims that Medis, an Iceland-based generic drug manufacturer, is one of the Teva units on the table.
Bloomberg also claimed that Teva is considering the sale of its respiratory treatment assets, although the publication’s anonymous sources said that a decision to sell has not been finalized and considerations are still at an early stage.
“Teva is looking at every opportunity to focus our business and streamline operations processes and structure,” the company said in a statement. “Beyond this update, Teva is not in a position to comment on market speculation.”
Teva is under increasing pressure to reduce its debt load, which has swelled to a whopping $35 billion following its acquisition of Allergan’s generics division. Any new asset sales would come in addition to the pending offloading of Teva’s women’s health and European cancer and pain treatment units.
Just last week, on the same day that the company reported lackluster Q2 earnings, slashed its full-year outlook, and cut its dividend by 75%, Teva CEO Yitzhak Peterburg said that asset sales will likely generate at least $2 billion, well above that $1 billion level that was previously forecasted.
Also last week, Moody’s said that Teva’s debt reduction has been slower than expected and lowered its credit rating. Moody’s hasn’t been the only analyst firm to question Teva recently, as Morgan Stanley’s David Risinger also chimed in this week.
“We believe that Teva’s disappointing generic business performance will take more time to improve given a combination of the generic industry’s intensifying secular challenges and Teva’s own difficulty in executing on its pipeline,” Risinger said in a note.
Risinger downgraded Teva to “underweight” and cut its price target to $16, which would represent a further 8.5% slide from Wednesday’s close.
Want more stock market analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teva Plunges to 10-Year Low, Credit Rating in Jeopardy
Shares of Teva Pharmaceuticals (TEVA - Free Report) , a favorite for investors chasing large dividend yields, fell more than 4.4%—and hit a 10-year intraday low—on Wednesday. Just says after the company reported sluggish Q2 earnings, investors are continuing to ditch the stock amid reports that Teva is desperately trying to sell off assets.
According to sources cited by Bloomberg, Teva is looking to ramp up asset sales in an effort to preserve its credit rating and cut its mounting debt. The report claims that Medis, an Iceland-based generic drug manufacturer, is one of the Teva units on the table.
Bloomberg also claimed that Teva is considering the sale of its respiratory treatment assets, although the publication’s anonymous sources said that a decision to sell has not been finalized and considerations are still at an early stage.
“Teva is looking at every opportunity to focus our business and streamline operations processes and structure,” the company said in a statement. “Beyond this update, Teva is not in a position to comment on market speculation.”
Teva is under increasing pressure to reduce its debt load, which has swelled to a whopping $35 billion following its acquisition of Allergan’s generics division. Any new asset sales would come in addition to the pending offloading of Teva’s women’s health and European cancer and pain treatment units.
Just last week, on the same day that the company reported lackluster Q2 earnings, slashed its full-year outlook, and cut its dividend by 75%, Teva CEO Yitzhak Peterburg said that asset sales will likely generate at least $2 billion, well above that $1 billion level that was previously forecasted.
Also last week, Moody’s said that Teva’s debt reduction has been slower than expected and lowered its credit rating. Moody’s hasn’t been the only analyst firm to question Teva recently, as Morgan Stanley’s David Risinger also chimed in this week.
“We believe that Teva’s disappointing generic business performance will take more time to improve given a combination of the generic industry’s intensifying secular challenges and Teva’s own difficulty in executing on its pipeline,” Risinger said in a note.
Risinger downgraded Teva to “underweight” and cut its price target to $16, which would represent a further 8.5% slide from Wednesday’s close.
Want more stock market analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>